1. Home
  2. MIRM vs BLCO Comparison

MIRM vs BLCO Comparison

Compare MIRM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$101.26

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$15.64

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
BLCO
Founded
2018
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.9B
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
MIRM
BLCO
Price
$101.26
$15.64
Analyst Decision
Strong Buy
Buy
Analyst Count
13
11
Target Price
$119.85
$18.45
AVG Volume (30 Days)
1.0M
414.0K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
74.59
N/A
EPS
N/A
N/A
Revenue
$19,138,000.00
$5,101,000,000.00
Revenue This Year
$26.22
$8.65
Revenue Next Year
$22.04
$5.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.47
52 Week Low
$43.50
$11.22
52 Week High
$114.99
$18.92

Technical Indicators

Market Signals
Indicator
MIRM
BLCO
Relative Strength Index (RSI) 51.95 39.74
Support Level $95.68 $15.20
Resistance Level $107.51 $16.41
Average True Range (ATR) 5.22 0.36
MACD -0.65 -0.04
Stochastic Oscillator 33.42 23.76

Price Performance

Historical Comparison
MIRM
BLCO

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: